Cargando…

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

BACKGROUND: Primary treatment of patients with advanced epithelial ovarian cancer consists of chemotherapy either before (neoadjuvant chemotherapy, NACT) or after primary surgery (adjuvant chemotherapy). The goal of primary treatment is no residual disease after surgery (R0 resection) what is associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Škof, Erik, Merlo, Sebastjan, Pilko, Gasper, Kobal, Borut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024662/ https://www.ncbi.nlm.nih.gov/pubmed/27679552 http://dx.doi.org/10.1515/raon-2016-0034

Ejemplares similares

Primary Debulking Surgery Versus Primary Neoadjuvant Chemotherapy for High Grade Advanced Stage Ovarian Cancer: Comparison of Survivals
por: Kobal, Borut, et al.
Publicado: (2018)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Potential of Osteopontin in the Management of Epithelial Ovarian Cancer
por: Cerne, Katarina, et al.
Publicado: (2019)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer
por: Lim, Myong Cheol, et al.
Publicado: (2017)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer
por: Hoff, John, et al.
Publicado: (2014)

Preoperative Serum CA-125 Level As a Predictor for The Extent of Cytoreduction in Patients with Advanced Stage Epithelial Ovarian Cancer
por: Merlo, Sebastjan, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art
por: Margioula-Siarkou, Chrysoula, et al.
Publicado: (2022)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
por: Baruah, Upasana, et al.
Publicado: (2015)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients
por: Yang, Xi-Lin, et al.
Publicado: (2022)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
por: Zeng, Long-Jia, et al.
Publicado: (2016)

Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer
por: Zhou, Mingyi, et al.
Publicado: (2020)

AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Wang, Yao, et al.
Publicado: (2016)

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
por: Gao, Yan, et al.
Publicado: (2019)

Locoregional Disease Control After External Beam Radiotherapy in 91 Patients with Differentiated Thyroid Carcinoma and pT4 Tumor Stage - A Single Institution Experience
por: Besic, Nikola, et al.
Publicado: (2018)

Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study
por: Zhou, Juan, et al.
Publicado: (2016)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
por: Kuhn, W, et al.
Publicado: (1999)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
por: Liu, Yuexi, et al.
Publicado: (2023)

Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy
por: Nantasupha, Chalaithorn, et al.
Publicado: (2022)

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
por: Perrone, Anna Myriam, et al.
Publicado: (2023)

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC
por: Fu, Yu, et al.
Publicado: (2023)

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Shin, Wonkyo, et al.
Publicado: (2020)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Soluble osteopontin concentrations in serum and ascites of women with advanced serous ovarian cancer
por: Černe, Katarina, et al.
Publicado: (2012)

A multi-institutional analysis of sequential versus ‘sandwich’ adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma
por: Onal, Cem, et al.
Publicado: (2018)

Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity
por: Tozzi, Roberto, et al.
Publicado: (2019)

Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer
por: Aigner, Karl R., et al.
Publicado: (2021)

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
por: Hegazy, Mohamed AF, et al.
Publicado: (2005)

Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites
por: Jakimovska, Marina, et al.
Publicado: (2014)

Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience
por: Liu, Yu, et al.
Publicado: (2020)

Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data
por: Seidler, Stephanie, et al.
Publicado: (2021)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Predicting tumor response and outcome of second-look surgery with (18)F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer
por: Aide, Nicolas, et al.
Publicado: (2020)

Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy
por: Buras, Andrea L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jr694eanl1mh113112h111nh54